A survey of current practices of physicians who treat adductor spasmodic dysphonia in the U.S.
We conducted a survey to determine the current practices of a subset of physicians in the United States who treat patients with adductor spasmodic dysphonia. Surveys were sent to 169 physicians listed in the National Spasmodic Dysphonia Association database, and responses were returned by 43 (25.4%). Almost all respondents (95.4%) indicated that they use botulinum toxin type A injections, either alone or in combination with other treatments, to treat adductor spasmodic dysphonia, and most (69.8%) inject the toxin under electromyographic guidance. However, there were wide variations in the amount of sterile saline used to reconstitute the toxin, the size of the initial dose, and the use of other treatment strategies.
Chang
Christopher Y
CY
Fauquier Ear Nose & Throat Consultants, PLC, Warrenton, VA 20186, USA. chang@FauquierENT.net
Chabot
Peter
P
Walz
Christopher M
CM
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D016001:Confidence Intervals; D003625:Data Collection; D004305:Dose-Response Relationship, Drug; D055154:Dysphonia / Q000175:diagnosis / Q000188:drug therapy*; D004576:Electromyography; D006801:Humans; D007273:Injections, Intramuscular; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians'; D011795:Surveys and Questionnaires; D014481:United States; D014827:Vocal Cords / Q000503:physiopathology
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A